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A common assumption underlying most genetic studies is that individu-
als with different genotypes respond similarly to exposure to internal
(epigenetic and background genotype effects) and external (ecological)
environments. Here we evaluate whether this assumption is true in
individuals with different genotypes of the gene coding for the apolipo-
protein E (Apo E) molecule, an important determinant of the
metabolic fate of plasma lipids and lipoproteins. We addressed whether
the utility of known risk factors of coronary heart disease (CHD) in
the prediction of CHD death in a 5-year follow-up is the same for the
two most common Apo E genotypes, o3/3 and o4/3, in two cohorts of
elderly Finnish men (age at baseline: 65–84 years), one in Eastern and
the other in Southwestern Finland. The CHD mortality rate was higher
in the o4/3 than in the o3/3 genotype in both cohorts (11.1 versus 7.8%,
Pr=0.281 in the Eastern cohort and 19.6 versus 8.2%, Pr=0.002 in
the Southwestern cohort). In the Eastern cohort, serum high density
lipoprotein (HDL) cholesterol level was identified as a strong predictor
of CHD death in the o3/3 genotype (b= −2.155, Pr=0.019). In the
Southwestern cohort, age (b=0.139, Pr=0.006), body mass index
(BMI) (b=0.149, Pr=0.016), and serum total cholesterol level (b=
0.453, Pr=0.051) were identified as strong predictors in the o3/3 geno-
type, as were smoking (b=0.236, Pr=0.008) and BMI (b= −0.124,
Pr=0.057) in the o4/3 genotype. The latter observation indicates that
in Southwestern Finland the probability of CHD death decreases with
increasing BMI in elderly men with the o4/3 genotype, while in their
counterparts with the o3/3 genotype the risk increases with increasing
BMI. This difference was statistically significant (Pr=0.002). These ob-
servations clearly argue against the assumption that individuals with
different genotypes respond similarly to exposures to internal and/or
external environments. These observations are consistent with a com-
plex pathobiology of CHD involving biochemical and physiological
agents that are under the influence of interactions between genetic and
environmental factors. Information about these interactions is necessary
for developing a more precise risk assessment and ultimately to im-
prove public health and clinical strategies to prevent this devastating
disease both at the individual and population levels.
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There is ample evidence that interindividual differ-
ences in levels of biochemical and physiological
traits, which are involved in the regulation of lipid
metabolism, glucose homeostasis, blood pressure,
and hemostasis, contribute significantly to in-
terindividual variation in the initiation, progres-
sion, and severity of atherosclerosis (1, 2).
Knowledge about levels of these traits is widely
used to predict the risk of coronary heart disease
(CHD), which is a clinically important manifesta-
tion of atherosclerosis. In clinical practice, and in
public health programs, individuals with extreme
values of the known risk factors are considered to
be candidates for lifestyle alterations and therapeu-
tic interventions.
Apolipoprotein E (Apo E), a structural con-
stituent of various plasma lipoprotein particles,
functions as an important determinant of the
metabolic fate of plasma lipids and lipoproteins (3,
4). Three major Apo E isoforms, o2, o3, and o4 have
been described (3, 4). Allelic variations responsible
for this protein polymorphism, denoted o2, o3, and
o4, are associated with variation in, and covariation
between, quantitative measures of lipid and lipo-
protein metabolism (4–9) and the presence of
CHD (3, 4) in many cross-sectional epidemiologi-
cal and clinical studies. Previously we reported that
the common genotypes of the gene that codes for
the three Apo E isoforms contribute to the predic-
tion of CHD death among elderly Finnish men in
a 5-year prospective follow-up (10). The influence
of the Apo E polymorphism on the levels of
plasma lipids and apolipoproteins may depend,
however, on the levels of other risk factors such as
body size, gender, and smoking status (11). Such
dependency suggests that the information about
CHD that a risk factor provides may vary among
the Apo E genotypes. In this study we address this
possibility by asking whether the utility of known
CHD risk factors in the prediction of CHD death
in a 5-year follow-up is the same for the two most
common Apo E genotypes o3/3 and o4/3 in two
cohorts of elderly Finnish men, one representing
Eastern and the other Southwestern Finland.
Methods
Sample
The Seven Countries Study, which included Fin-
land, was initiated in the late 1950’s to study
cardiovascular disease mortality and morbidity
and related risk factor levels in different popula-
tions (12, 13). The original Finnish cohorts con-
sisted of men born between 1900 and 1919 and
living in two geographically defined rural areas,
one in Eastern (n=823) and the other in South-
western Finland (n=888). Of these 1711 men, 766
(45%) were still alive in 1984, when baseline assays
for the current study were performed. Knowledge
about both the Apo E genotype and risk factor
levels was available from 625 (82%) of these men.
In this sample, 559 (89%) had either the o3/3 or the
o4/3 genotype. The Eastern cohort was comprised
of 256 men, of whom 193 (75%) had the o3/3
genotype. The Southwestern cohort was comprised
of 303 men, of whom 196 (65%) had the o3/3
genotype.
At the time of the follow-up survey in 1989, of
the 559 men who had either the o3/3 or the o4/3
genotype, 387 (183 in the Eastern cohort and 204
in the Southwestern cohort) were still alive and 172
(73 (29%) in the Eastern cohort and 99 (33%) in
the Southwestern cohort) had died during the 5-
year follow-up period. The vital status of each man
was ascertained through personal contacts, except
for 11 men whose vital status was ascertained
through the Finnish Population Registry. Death
certificates and hospital records were obtained for
all the deceased men and the cause of death was
coded according to fixed criteria (13).
Study protocol
Both baseline and follow-up surveys of each geo-
graphic region were conducted during the same
month of the year, October in the East and
November in the Southwest. Complete details of
the study protocols of the 1984 baseline survey and
the follow-up survey in 1989, are given elsewhere
(14, 15). All participants fasted for at least 4 h
before their visit to the clinic (mean fasting time
was 13 h, standard deviation 5 h). At the clinic,
blood samples were drawn from the antecubital
vein for laboratory analyses. Body weight was
measured to the nearest 0.1 kg in light undergar-
ments. Height was measured only in 1959, when
the men were first seen in connection with the
Seven Countries Study. This height was used to
calculate body mass index (BMI, kg/m2), a mea-
sure of body size used in the current analyses.
Smoking status was assessed using a standard
questionnaire (13). Participants were classified into
two categories: smokers of cigarettes, cigars or
pipes, and non-smokers. Participants who had not
smoked for more than 1 year before the survey
were classified as non-smokers.
Blood pressure was measured by a trained nurse.
After at least a 5 min rest at the end of clinical
examination, two successive readings were taken
from the right arm using a mercury manometer
with a 12×33.5 cm cuff. Readings were taken to
the nearest 2 mmHg and complete disappearance
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of the fifth phase of Korotkoff sounds was
recorded as the diastolic pressure. We used the
mean values of the two readings for the analyses
presented in this study.
Laboratory measurements
Serum total and high density lipoprotein (HDL)
cholesterol concentrations were assayed using an
enzymatic method (Monotest, Boehringer
Mannheim, GmbH, Mannheim, Germany) and an
Olli 3000 photometer (Kone Oy, Finland). Total
cholesterol was determined from a fresh serum
sample (16). HDL cholesterol was measured after
precipitation of very low density lipoprotein
(VLDL) and low density lipoprotein (LDL) parti-
cles with dextran-magnesium-chloride (16). Apo E
phenotypes were determined using sera stored at
−20°C until utilized in 1992. Apo E phenotyping
was carried out according to a modification of the
method of Havekes et al. (17), which was based on
isoelectric focusing of delipidated serum followed
by immunoblotting using rabbit anti-human Apo
E antiserum. Apo E genotypes were inferred from
the isoform phenotypes.
Statistical analysis
Baseline differences between the carriers of the
o3/3 and o4/3 genotypes were tested for statistical
significance by the analysis of variance (means)
and Bartlett’s test (variances) for quantitative risk
factors and x2-statistics for categorical variables,
seperately for the Eastern and the Southwestern
cohorts. The cohorts were analyzed separately be-
cause there is ample evidence that the natural
history of CHD differs between them (12, 13, 18,
19). The following risk factors were considered in
the analysis: age, BMI, systolic and diastolic blood
pressure, serum total and HDL cholesterol levels,
and smoking status.
The Kaplan–Meier product limit method (20)
was used to estimate the Apo E genotype-specific
probability of surviving, or if an individual died,
not dying from CHD, as a function of time. A
logistic regression analysis (21) was employed to
estimate the intragenotypic probability of CHD
death in a 5-year follow-up using a model where
each proposed CHD risk factor was considered in
a univariable model, separately for the carriers of
the o3/3 and o4/3 genotypes. Each risk factor that
was associated with the probability of CHD death
within at least one of the two Apo E genotype
strata at the Pr50.20 level of statistical signifi-
cance in these analyses was selected for further
analyses to assess whether the observed association
is homogeneous across the two Apo E genotype
strata. This relatively high significance level was
selected because the use of a more traditional test
criterion (Pr50.05) at this point could result in
disregarding risk factors that contribute signifi-
cantly to the prediction of CHD probability of
death when considered in a multivariable model
(21). This analysis was carried out separately for
the Eastern and the Southwestern cohorts.
In order to test homogeneity of the observed
Apo E genotype-specific associations between the
probability of CHD death and a proposed risk
factor, we first employed a complete model where
the Apo E genotype, a proposed CHD risk factor,
and the interaction between the effects of the two
Apo E genotypes and levels of the proposed risk
factor were considered. The effects of the two Apo
E genotypes were included in the model as a binary
variable where the o3/3 genotype was coded as 0
and the o4/3 was coded as 1. Interaction between
the Apo E genotypes and levels of a CHD risk
factor was modeled as a product of this binary
variable and the risk factor considered. The logit
under this most complete model was parameterized
as follows: logit of the probability of CHD death
=a+b1*o+b2*X+b3*o*X, where o represents the
code of Apo E genotype and X represents the level
of the risk factor of interest. Under this parameter-
ization the logit of the probability of CHD death is
a+b2*X for the carriers of the o3/3 genotype (o=
0) and (a+b1)+ (b2+b3)*X for the carriers of the
o4/3 genotype (o=1).
Second, we considered a reduced model, where
the parameter b3 was constrained to 0 and the
remaining parameters of the model were re-esti-
mated. In this reduced model the estimate of the
parameter a is an estimate of the intercept for the
logit in the carriers of the o3/3 genotype, and the
sum of the estimates of a and b1 is an estimate of
intercept for the logit in the carriers of the o4/3
genotype. The estimate of the b2 parameter in this
reduced model is an estimate of the slope of the
logit shared by both genotype classes. The maxi-
mum value of the likelihood of this reduced ‘no
interaction’ model was compared with the maxi-
mum value of the likelihood of the complete
model, using a likelihood ratio criterion with one
degree of freedom to test whether the slopes of the
logits were homogeneous among the two geno-
types. Rejection of the null hypothesis that a com-
mon slope explains these data supports the
hypothesis that the ability to predict the probabil-
ity of CHD death from the level of a risk factor is
dependent on the individual’s Apo E genotype.
All statistical analyses were performed with the
SAS statistical software package. Statistical tests
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Table 1. Description of the data at baseline
Eastern cohort Southwestern cohort
o3/3 o4/3 o3/3 o4/3
n=193 n=63 n=196Risk factor n=107
Age
71.5 (4.9)1 71.7 (4.0)Mean (SD) 73.2 (5.2) 73.0 (5.4)
BMI (kg/m2)
25.5 (4.1) 25.2 (3.9)Mean (SD) 26.1 (4.2) 25.8 (3.8)
Serum total cholesterol (mmol/l)
6.2 (1.3) 6.3 (1.4)Mean (SD) 6.1 (1.1) 6.3 (1.4)2
Serum HDL cholesterol (mmol/l)
1.2 (0.3) 1.2 (0.3)Mean (SD) 1.2 (0.3) 1.2 (0.3)
Systolic blood pressure (mmHg)
150.8 (23.0) 146.8 (21.0)Mean (SD) 156.9 (21.6) 157.0 (22.0)
Diastolic blood pressure (mmHg)
85.3 (10.6) 82.8 (11.2) 89.6 (9.8)Mean (SD) 87.9 (12.1)
Smoking status
20.2 24.0 16.8Current (%) 20.6
1 Heterogeneity of variance between the two genotype strata significant at Pr=0.038.
2 Heterogeneity of variance between the two genotype strata significant at Pr=0.008.
that achieved the Pr50.05 level of probability
were considered to be statistically significant unless
otherwise stated.
Results
Comparison of the risk factor levels at baseline between
the two common Apo E genotypes
The Apo E genotype-specific means and standard
deviations of risk factor levels at baseline are given
separately for the Eastern and the Southwestern
cohorts in Table 1. No statistically significant het-
erogeneity was observed for average age, BMI,
serum total and HDL cholesterol, systolic and
diastolic blood pressure levels, and proportion of
current smokers between the two Apo E genotypes
in either cohort. In contrast, variance of age in the
Eastern cohort was significantly larger in the carri-
ers of the o3/3 genotype than in the carriers of the
o4/3 genotype (Pr=0.038). The variance of serum
total cholesterol in the Southwestern cohort was
significantly larger in the carriers of the o4/3 geno-
type than in the carriers of the o3/3 genotype
(Pr=0.008).
Comparison of CHD death between the two common
Apo E genotypes
During the 5-year follow-up period, a total of 22
CHD deaths were recorded in the Eastern cohort.
Of these, 15 were carriers of the o3/3 genotype
(7.8% of the o3/3 individuals) and 7 were carriers
of the o4/3 genotype (11.1% of the o4/3 individu-
als). In the Southwestern cohort, a total of 37
CHD deaths were recorded. Of these, 16 were
carriers of the o3/3 genotype (8.2% of the o3/3
individuals) and 21 were carriers of the o4/3 geno-
type (19.6% of the o4/3 individuals). Comparison
of the Kaplan–Meier survival probability curve
for the carriers of the o3/3 genotype with the curve
for the carriers of the o4/3 genotype indicates that
the observed heterogeneity in CHD mortality rates
between the two Apo E genotypes in the Eastern
cohort was not statistically significant (Pr=0.281)
(Fig. 1A). In contrast, the observed heterogeneity
in the CHD mortality rates between genotypes was
statistically significant in the Southwestern cohort
(Pr=0.002) (Fig. 1B).
Predictive utility of known risk factors among the carriers
of the two common Apo E genotypes
In the Eastern cohort, serum HDL cholesterol was
identified as a statistically significant predictor of
CHD death in the 5-year follow-up in the o3/3
genotype at the Pr=0.019 level of probability
(Table 2). BMI contributed to the prediction of
CHD death at a Pr=0.104 level of statistical sig-
Fig. 1. Illustrations of the Apo E genotype-specific survival probability curves, separately for the Eastern (A) and the Southwestern
(B) male cohorts. The Kaplan–Meier product limit method was used to estimate probability of surviving, or if an individual died,
not dying from CHD, as a function of time, separately for the o3/3 and o4/3 genotypes in each cohort. The null hypothesis that the
curves are homogeneous among the genotypes could not be rejected in the Eastern cohort (Pr=0.281) while in the Southwestern
cohort it was rejected (Pr=0.002).
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Table 2. Predictive utility of known risk factors among the carriers of the two common Apo E genotypes, separately for the two cohorts
Eastern cohort Southwestern cohort
Risk factor Parameters Estimate x2 Pr Estimate x2 Pr
Age
b2 0.054 1.050 0.306o3/3 0.139 7.435 0.006
b2+b3 0.069 0.449 0.503o4/3 0.031 0.466 0.495
Interaction b3 * * * −0.108 2.469 0.116
BMI (kg/m2)
b2 0.107 2.640 0.104o3/3 0.149 5.819 0.016
o4/3 b2+b3 0.064 0.397 0.529 −0.124 3.633 0.057
b3 −0.044 0.134 0.714Interaction −0.272 9.278 0.002
Serum total cholesterol (mmol/l)
o3/3 b2 −0.135 0.394 0.530 0.453 3.805 0.051
b2+b3 0.354 1.897 0.168o4/3 0.294 3.004 0.083
Interaction b3 0.489 2.147 0.142 −0.159 0.300 0.584
Serum HDL cholesterol (mmol/l)
b2 −2.155 5.511 0.019o3/3 −0.895 0.901 0.343
b2+b3 0.159 0.013 0.908o4/3 −1.357 2.588 0.108
Interaction b3 2.314 1.782 0.182 −0.462 0.124 0.725
Systolic blood pressure (mmHg)
o3/3 b2 −0.009 0.545 0.466 0.012 1.024 0.312
o4/3 b2+b3 −0.018 0.794 0.373 0.003 0.085 0.770
b3 * * *Interaction * * *
Diastolic blood pressure (mmHg)
b2 −0.016 0.373 0.542o3/3 0.028 1.146 0.285
b2+b3 −0.004 0.014 0.904 −0.014o4/3 0.492 0.483
b3 * * *Interaction * * *
Smoking status
b2 −1.335 2.313 0.128o3/3 0.551 0.751 0.386
o4/3 b2+b3 1.012 1.405 0.236 1.438 6.995 0.008
b3Interaction 2.347 3.567 0.059 0.887 1.229 0.268
* No test was carried out when Pr\0.200 for each genotype.
nificance and smoking status at the Pr=0.128 level
of statistical significance. In contrast, among the
carriers of the o4/3 genotype, no risk factor was
detected as a predictor of CHD death at the Pr5
0.05 level of statistical significance. Serum total
cholesterol was the only risk factor that contributed
to the prediction of CHD death at the Pr50.200
level of statistical significance in this genotype class.
In the Southwestern cohort, age, BMI, and serum
total cholesterol level were identified as significant
predictors of CHD death among the carriers of the
o3/3 genotype at the Pr=0.05 level of probability
(Table 2). In those with the o4/3 genotype, BMI
(Pr=0.057), serum total cholesterol (Pr=0.083),
serum HDL cholesterol (Pr=0.108), and smoking
status (Pr=0.008) each contributed to the predic-
tion of CHD death.
Heterogeneity of the predictive utility of different risk
factors among the carriers of the two common Apo E
genotypes
In the Eastern cohort, the null hypothesis that the
slopes of the logits of CHD death are homogeneous
across the two common Apo E genotypes was
rejected (Pr=0.059) when an association between
the probability of CHD death and smoking status
was tested in a bivariable model (Table 2). In this
case, the estimate of the slope was negative for the
carriers of the o3/3 genotype and positive for the
carriers of the o4/3 genotype. No statistically signifi-
cant heterogeneity (Pr50.05) of the slopes of the
logits could be detected in this cohort when BMI
and/or serum total and/or HDL cholesterol level
were considered as predictors of CHD death.
In the Southwestern cohort, the null hypothesis of
the homogeneity of the slopes of the logits of CHD
death was rejected (Pr=0.002) in a bivariable model
when BMI was considered as a predictor (Table 2).
In this case, the estimate of the slope was positive
for the carriers of the o3/3 genotype and negative for
the carriers of the o4/3 genotype. The probability of
CHD death as a function of BMI based on these
estimates in the Southwestern cohort is given in Fig.
2B, separately for the carriers of the o3/3 and o4/3
genotypes. For comparison, CHD death probabili-
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Fig. 2. Illustrations of the Apo E genotype-specific probabilities of CHD death as a function of BMI (kg/m2), separately for the
Eastern (A) and the Southwestern (B) male cohorts. A logistic regression analysis was employed to estimate these probabilities.
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Stengård et al.
ties as a function of BMI, based on the estimates
obtained in the Eastern cohort, are given in Fig.
2A. No other statistically significant heterogeneity
(Pr50.05) of the slopes of the logits could be
detected in the Southwestern cohort when the
other predictors of CHD death (age, serum total
and HDL cholesterol levels, and smoking status)
were considered separately.
Discussion
It is widely accepted that the relative importance of
risk factors in the prediction of CHD endpoints
may vary among populations (1, 2, 13). There is
also accumulating evidence that within a popula-
tion (level A, Fig. 3) there may be subgroups of
individuals (levels B–D, Fig. 3) which have differ-
ent risk profiles. Recently subgroups differing in
age have attracted particular attention because the
predictive power of many risk factors may dimin-
ish in the elderly (22–25). Here we further consid-
ered the subdivision of the population by
genotype. Our analysis considers the relative im-
pact of area of residence, age stratification, and the
Apo E genotype on the influence of variation in the
levels of risk factors on the variation in risk of
CHD death. There are both an historical and a
practical rationale for considering these hierarchi-
cally defined subgroups. Initial observations in the
1950’s established that both the average levels of
most risk factors and CHD morbidity and mortal-
ity rates are different in Eastern Finland and
Southwestern Finland (12, 13, 18, 19). Because the
knowledge about the Apo E status was available
only from the elderly men, age was considered in
the hierarchy prior to the Apo E genotype. The
rationale for performing a stratified evaluation of
CHD risk is a response to clinical and public
health needs to identify individuals (or patients)
(level E, Fig. 3) who have a similar prognosis
and/or who are candidates for similar therapeutic
interventions.
Geographic and age-specific differences in the
contributions of known risk factors to the prediction of
CHD death
This study, together with other studies (10, 22,
26–28), demonstrates that the risk factors, which
are initially identified as predictors of CHD in
middle-aged men, are also predictors in elderly
men. The combinations of risk factors that were
identified as predictors of CHD death in a 5-year
follow-up in Eastern and Southwestern Finland in
this study and in our earlier study (10) differ,
however, from the combinations reported to be
present in these cohorts in the 1950’s, when the
men were middle-aged (18, 19). In the latter stud-
ies, serum total cholesterol level, smoking, and
blood pressure were major predictors of CHD end-
points in both cohorts. In the elderly survivors of
these cohorts studied here, none of these risk fac-
tors was identified as a predictor of CHD death in
Eastern Finland and only serum total cholesterol
level and smoking status were predictors in South-
western Finland (10) at a Pr50.05 level of statisti-
cal significance. A fraction of the observed age and
geography-related differences in the predictive
power of the CHD risk factors may reflect a differ-
ence in the age-specific death rates in the two
subpopulations. In the Eastern cohort there has
been an excess of individuals who have had ex-
treme high risk factor values and who have died of
CHD in the past (12). Survivors with high risk
factor values may be less susceptible to atherogene-
sis. An alternative explanation is that the age-re-
lated changes in the predictive power of CHD risk
factors may reflect biochemical and physiological
changes, which are associated with the aging pro-
cess per se, that alter an individuals atherogenic
potential. On average, these age-dependent
changes may differ between these subpopulations.
There is also evidence that variation in the ge-
netic susceptibility of CHD reflected by measures
of variation in the Apo E gene may vary among
different subgroups of individuals. In our earlier
Fig. 3. In this paper we have performed a stratified risk assess-
ment. Here we illustrate how different strata are defined. The
purpose of the graph is to help visualize how the information
obtained in this study can be employed in public health (level
A) and in clinical (level E) practice. The letters B, C, and D
refer to the levels where the splits are made in area of residence,
age, and the Apo E genotype, respectively.
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study we found that different Apo E genotypes
were predictors of CHD death in elderly Finnish
men both in Eastern Finland and in Southwestern
Finland (10). The odds of CHD death during a
5-year follow-up in the carriers of the high risk
o4/3 genotype were approximately 2.5 higher than
in the carriers of the o3/3 genotype in the South-
western cohort while in the Eastern cohort the
respective ratio was 1.5. In contrast, in the Eastern
cohort the odds of CHD death was approximately
7.5 times higher in the carriers of two rare o4/2 and
o4/4 genotypes when compared with carriers of the
o3/3 genotype. Consistent with these earlier obser-
vations, comparisons of the disease-specific sur-
vival curves in the present study demonstrate an
excess of CHD mortality among the carriers of the
o4/3 genotype as compared with carriers of the
o3/3 genotype. The observed difference was statisti-
cally significant in the Southwestern cohort but not
in the Eastern cohort. Our earlier observation that
the relative frequency of the o4 allele was lower in
the Eastern cohort than in the Southwestern co-
hort (29) suggests that a fraction of the geographic
differences in the predictive power of the o4/3
genotype in this study may reflect a higher selective
mortality against the o4 allele in the past in the
Eastern cohort than in the Southwestern cohort.
Carriers of the o4 allele are hypothesized to be
more prone to CHD than individuals who do not
carry this allele because on average they have
higher serum total cholesterol levels (3, 4). Consis-
tent with this hypothesis both the average serum
total cholesterol level and its intragenotypic varia-
tion were higher in the carriers of the o4/3 geno-
type than in the carriers of the o3/3 genotype in
our study in both cohorts. The difference in the
interindividual variance of serum total cholesterol
level between genotypes was statistically significant
in the Southwestern cohort. Our observation that
the CHD mortality rate was higher in the o4/3
genotype than in the o3/3 genotype in this cohort
may thus be a consequence, at least in part, of a
larger proportion of individuals with hypercholes-
terolemia among those with the o4/3 genotype,
which is evident from the significantly greater dis-
persion of serum total cholesterol level in the
Southwestern cohort.
Influence of the two most common Apo E genotypes on
predictive utility of known risk factors within population
and age-defined strata
Most genetic studies assume that individuals with
different genotypes respond similarly to exposures
to internal (epigenetic and background genotype
effects) and external (ecological) environments
(30). The goal of such studies is to identify genetic
polymorphisms that have an independent influence
on interindividual variation in the risk of disease.
Only a few studies have been carried out with the
intention of characterizing the contribution of ge-
netic variation to interindividual differences in the
relationships between various risk factors and of
differences in the responses to exposures to inter-
nal and/or external environments. The biological
fact that the contribution of any genetic or envi-
ronmental variation to the variation in the risk of
CHD must be translated through variation in, and
covariation between, various biochemical and
physiological risk factors suggests, however, that
knowledge about the other aspects of the genetic
architecture of CHD may be as important for risk
assessment as is the knowledge about the average
genotypic differences in the risk factor levels and in
the risk of the disease. This reality is demonstrated
by the influence of the Apo E polymorphism on
covariation between lipid and lipoprotein traits (9).
The proportion of the individuals that exceed a
threshold for high risk determined by multiple
traits is different in different genotype groups even
when the average levels of the risk factors may not
differ. Recent evidence that the association be-
tween the amount of coronary calcification (an
index of atherosclerosis) and plasma lipid levels
may be different in different Apo E genotypes (31)
documents the importance of the Apo E genotypes
in determining the biological context in which the
atherosclerotic process is occurring. Our study fur-
ther documents that the statistical relationship be-
tween the risk of CHD death and established risk
factors such as age, BMI, serum total and HDL
cholesterol level, and tobacco smoking in elderly
men may be different in different Apo E genotypes.
However, since the influences of the Apo E geno-
types on this relationship for a particular risk
factor (e.g., BMI) were different in the Eastern and
the Southwestern cohorts, our study suggests
statistical interactions between genotype variation
and variation in measures of risk that are indexed
by area of residence.
Clinical and public health implications of our observations
In clinical practice, knowledge about risk factor
levels is widely used to identify individuals who are
at increased risk. High risk individuals are consid-
ered to be candidates for lifestyle alterations and
related therapeutic interventions. The utility of ge-
netic information both at the clinical level (level E,
Fig. 3) and at the public health level (level A, Fig.
3) depends on whether it improves risk assessment.
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Our study suggests that from the risk assessment
point of view an important benefit of genetic knowl-
edge is that a trait may be a significant predictor of a
disease outcome only in individuals with a particular
geno(me)type, even though it is not identified as a
predictor in studies of the population at large. For
instance, BMI is a well-known risk factor that has
been positively associated with the risk of CHD in
some populations (1, 2, 25) but not in others (1, 2).
We did not identify BMI as a predictor of CHD
death in elderly Finnish men either in the Eastern or
the Southwestern cohort in this study nor in our
earlier study (10). However, in the present study
variation in BMI was significantly associated with
variation in the risk of CHD death both in the o3/3
(Pr=0.016) and the o4/3 (Pr=0.057) genotype
groups in the Southwestern cohort. The estimate of
the slope was positive in the former genotype group
and negative in the latter genotype group, indicating
that in Southwestern Finland the risk of CHD death
increases with increasing BMI in elderly men with
the o3/3 genotype, while the relative risk declines
with increasing BMI in their counterparts with the
o4/3 genotype. Since weight reduction is expected to
lower the risk of CHD in obese individuals (32, 33), a
therapeutic implication of our result is that obese
elderly men in the o3/3 genotype group in South-
western Finland are targets for intensified weight
reduction intervention(s).
A statistically significant decline in the risk of
CHD death with advancing BMI (e.g., in elderly
men with the o4/3 genotype in Southwestern Fin-
land) is an unexpected observation that has no
obvious explanation. One possibility is that a combi-
nation of obesity and the o4/3 genotype, both of
which are associated with a highly atherogenic risk
factor profile, has been extremely deleterious for
middle-aged men in the Southwestern cohort where
the CHD mortality rate has otherwise been low in
the past. Alternatively, there would have to be other,
unmeasured factors indexed by low BMI, which
together with the o4/3 genotype increase the risk of
CHD death in elderly men, and which have persisted
in the Southwestern cohort where the CHD mortal-
ity rate has been low in the past but not in the
Eastern cohort where the CHD mortality rate has
been high. In any case, these findings serve as a
document to why we failed to identify BMI as a
predictor of CHD death in our earlier studies of the
same cohort when the contribution of the Apo E
genotypes was not considered.
In conclusion, a major finding of this study is that
in elderly Finnish men the two common Apo E
genotypes, together with the area of residence, serve
to define contexts in which known risk factors such
as age, BMI, serum total and HDL cholesterol, and
tobacco smoking are operating in a different manner
to determine the risk of CHD death. Although the
first-order interactions reported here can reflect only
a fraction of the complex pathobiology of CHD,
they are consistent with the fact that CHD death is
an emergent property of complex interactions be-
tween many genetic and environmental factors. Our
observations make clear that to understand this
complex pathobiology it is incumbent that we focus
on the interactions between agents involved in
causality rather than seeking their independent in-
variant properties. Stratified risk assessment serves
as a strategy that takes advantage of the prognostic
importance of these interactions. Identification of
prognostically important strata, such as those
defined by area of residence, age, and the Apo E
genotype in this study, can result in a more precise
risk assessment and ultimately improve clinical and
public health strategies to prevent the disease both at
individual and population levels.
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